Lord, Abbett & Co. LLC Rigel Pharmaceuticals Inc Transaction History

Lord, Abbett & Co. LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.67 - $3.19 $2.95 Million - $14.1 Million	-4,409,833 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.22 - $3.45 $171,439 - $266,426	77,225 Added 1.78%	4,409,833 $13.2 Million
Q4 2021 Feb 11, 2022	SELL	$2.36 - $3.57 $99,334 - $150,264	-42,091 Reduced 0.96%	4,332,608 $11.5 Million
Q3 2021 Nov 09, 2021	SELL	$3.5 - $4.5 $204,137 - $262,462	-58,325 Reduced 1.32%	4,374,699 $15.9 Million
Q2 2021 Aug 11, 2021	SELL	$3.09 - $4.54 $1.31 Million - $1.92 Million	-423,023 Reduced 8.71%	4,433,024 $19.2 Million
Q1 2021 May 11, 2021	BUY	$3.35 - $4.93 $16.3 Million - $23.9 Million	4,856,047 New	4,856,047 $16.6 Million

335K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.93B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.